Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial

BACKGROUND: The programmed death-1 (PD-1) inhibitor nivolumab prolongs disease-free survival in patients with muscle-invasive urothelial carcinoma (MIUC). OBJECTIVE: To evaluate the effects of nivolumab on health-related quality of life (HRQoL) after radical resection in patients with MIUC. DESIGN,...

Descripción completa

Detalles Bibliográficos
Autores principales: Witjes, Johannes Alfred, Galsky, Matthew D., Gschwend, Jürgen E., Broughton, Edward, Braverman, Julia, Nasroulah, Federico, Maira-Arce, Mario, Ye, Xiaomei, Shi, Ling, Guo, Shien, Hamilton, Melissa, Bajorin, Dean F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062393/
https://www.ncbi.nlm.nih.gov/pubmed/35288066
http://dx.doi.org/10.1016/j.euo.2022.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062393/
https://www.ncbi.nlm.nih.gov/pubmed/35288066
http://dx.doi.org/10.1016/j.euo.2022.02.003

Ejemplares similares